Search clinical trials for: anacetrapib

Total 42 results

Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) (DEFINE)

Coronary Heart Disease (CHD) | CHD Risk-Equivalent Disease
Eli Lilly and Company

Completed

A Study to Measure the Amount of Evacetrapib That Enters the Blood Stream in Healthy Participants

Healthy Volunteers

United Kingdom
University of Oxford
Merck Sharp & Dohme LLC

Active, not recruiting

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL)

Atherosclerotic Cardiovascular Disease

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC

Completed

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

Dyslipidemia
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

Ambulatory Blood Pressure
Cambridge University Hospitals NHS Foundation Trust
British Heart Foundation Cambridge Centre of Excellence

Completed

The Effect of Anacetrapib on Vascular Function and Arterial Stiffness (REVEAL-Vasc)

Atherosclerotic Cardiovascular Disease | Vascular Disease

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Hypercholesterolemia | Hyperlipidemia
Merck Sharp & Dohme LLC

Terminated

MK0859 Dose-Ranging Study (0859-003)

Hypercholesterolemia | Mixed Hyperlipemia
Merck Sharp & Dohme LLC

Completed

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) (REALIZE)

Hyperlipoproteinemia Type II | Hypercholesterolemia, Familial
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Terminated

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

Hyperlipoproteinemia Type II | Homozygous Familial Hypercholesterolemia
Eli Lilly and Company

Completed

A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

Cardiovascular Disease

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib in Participants With Abnormal Cholesterol

Dyslipidemia

United States
Eli Lilly and Company

Completed

A Study of Different Particle Sizes of Evacetrapib in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Completed

A Study of Evacetrapib in Healthy Japanese Participants

Healthy Volunteers

Japan
Eli Lilly and Company

Terminated

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Hypercholesterolemia

Japan
Eli Lilly and Company

Completed

A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

Hepatic Insufficiency

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib (LY2484595) in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company
The Cleveland Clinic

Terminated

A Study of Evacetrapib in High-Risk Vascular Disease (ACCELERATE)

Cardiovascular Diseases

United States, Brazil, Israel, Italy, Korea, Republic of, Mexico, Japan, Russian Federation, Germany, France, Spain, Taiwan, Bulgaria, Netherlands, Ukraine, Austria, Denmark, Australia, Sweden, Argentina, Canada, Hungary, Poland, Romania and more
Eli Lilly and Company

Completed

Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

Study of Food on Evacetrapib (LY2484595) in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Terminated

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (ACCENTUATE)

Hyperlipidemia

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY2484595 in Japanese Subjects

Dyslipidemias

Japan
Eli Lilly and Company

Completed

A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants

Healthy Volunteers

China
Eli Lilly and Company

Completed

A Study of Evacetrapib in Japanese and Non-Japanese Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Terminated

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

Hypercholesterolemia

Japan
Eli Lilly and Company

Completed

A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib and Digoxin in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2484595 on the Electrical Activity of the Heart

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2484595 in Healthy Subjects

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Dyslipidemia

United States, Netherlands, Germany, Denmark, Poland, United Kingdom
Eli Lilly and Company

Completed

A Study of LY2484595 on Pharmacokinetics in Healthy Participants

Healthy Participants

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib and Rifampin in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib in Healthy Female Participants

Healthy Volunteers

United States

3

Subscribe